HUP0500871A2 - 5-Ariltetrazol-vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
5-Ariltetrazol-vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0500871A2 HUP0500871A2 HU0500871A HUP0500871A HUP0500871A2 HU P0500871 A2 HUP0500871 A2 HU P0500871A2 HU 0500871 A HU0500871 A HU 0500871A HU P0500871 A HUP0500871 A HU P0500871A HU P0500871 A2 HUP0500871 A2 HU P0500871A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- nhc
- benzyl
- independently
- nhr5
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 15
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 4
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 4
- 125000006375 C2-C10 alkynyl group Chemical group 0.000 abstract 4
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- -1 -OH Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány (Ia) általános képletű 5-ariltetrazol-vegyületekre, afenti 5-ariltetrazol-vegyületeket hatásos mennyiségben tartalmazógyógyszerkészítményekre vonatkozik. A találmány tárgya továbbá a fentivegyületek alkalmazása gyulladásos betegsegek, reperfúziós betegségekvagy hiperuricemia kezelésére alkalmas gyógyszerkészítményekalkalmazására. A képletben R1 jelentése CO2R4, R2 jelentése egymástólfüggetlenül halogénatom, -NO2, -CN, -OH, -N(R5)(R5), -OR5, -C(O)R5, -OC(O)R5, -C(O)NHC(O)R5, -(C1-C10)al- kil, -(C2-C10)alkenil, -(C2-C10)alkinil, -(C3-C10)cikloalkil, -(C8-C14)bi- cikloalkil, -(C5-C10)cikloalkenil, -(C3-C10)heterolociklus, -fenil, -naftil, -benzil, -CO2R5, -C(O)OCH(R5)(R5), -NHC(O)R5, -NHC(O)-NHR5, -C(O)NHR5, -OC(O)R5,-OC(O)OR5, -SR5, -S(O)R5, vagy -S(O)2R5, R3 jelentése -H, -halogénatom, -NO2, -CN, -OH, -N(R5)(R5), -O(CH2)mR5, -C(O)R5, -C(O)NR5R5, -C(O)NH(CH2)m(R5), -OCF3, -benzil, -CO2CH(R5)(R5), -(C1-C10)alkil, -(C2-C10)alkenil, -(C2-C10)alkinil, -(C3-C10)cikloalkil, -(C8-C14)bicikloalkil, -(C5-C10)cikloalkenil, -naftil, -(C3-C10)heterociklus, -CO2(CH2)mR5, -NHC(O)R5, -N(R5)C(O)R5, -NHC(O)NHR5,-OC(O)(CH2)mCHR5R5, -CO2(CH2)mCHR5R5, -OC(O)OR5, -SR5, -S(O)R5, -S(O)2R5, -S(O2)NHR5, vagy R4 jelentése -(C5)heteroaril, -(C6)heteroaril, fenil, naftil, vagy benzil, R5 jelentése egymástólfüggetlenül -H, -CF3, -(C1-C10)alkil, -benzil, -adamantil, -morfolinil, -pirrolidil, -piridiloxid, -pirrolidinildion, -piperidil,-(C2-C10)alkenil, -(C2-C10)alkinil, -(C3-C10)cikloalkil, -(C8-C14)bicikloalkil, -(C3-C10)heterociklus, vagy R6 jelentése egymástólfüggetlenül -H, -halogénatom, -NO2, -CN, -OH, -CO2H, -N((C1-C10)alkil-(C1-C10)alkil, -O(C1-C10)alkil, -C(O)(C1-C10)alkil, -C(O)NH(CH2)- (C1-C10)alkil, -OCF3, -benzil, -CO2(CH2)mCH((C1-C10)alkil-(C1-C10)alkil),-C(O)H, -CO2(C1-C10)alkil, -(C1-C10)alkil, -(C2-C10)alkenil, -(C2-C10)alkinil, -(C3-C10)cikloalkil, -(C8-C14)bicikloalkil, -(C5-C10)cikloalkenil, -(C5)heteroaril, -(C6)heteroaril, -fenil, naftil, -(C3-C10)heterociklus, -CO2(CH2)m(C1-C10)alkil, -CO2(CH2)mH, -NHC(O)-(C1-C10)alkil, -NHC(O)NH(C1-C10)alkil, -OC(O)(C1-C10)alkil, -OC(O)O(C1-C10)alkil, -SO2NHR5, vagy -SO2NH2, n jelentése 0-4 értékűegész szám, m jelentése egymástól függetlenül 0-8 értékű egész szám ésp jelentése egymástól függetlenül 0-5 értékű egész szám.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/197,609 US7078423B2 (en) | 2002-07-18 | 2002-07-18 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
PCT/US2003/022462 WO2004009563A1 (en) | 2002-07-18 | 2003-07-17 | 5-aryltetrazole compounds, compositions thereof, and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0500871A2 true HUP0500871A2 (hu) | 2005-12-28 |
HUP0500871A3 HUP0500871A3 (en) | 2006-11-28 |
Family
ID=30769479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0500871A HUP0500871A3 (en) | 2002-07-18 | 2003-07-17 | 5-aryltetrazole compounds, compositions thereof and their use |
Country Status (16)
Country | Link |
---|---|
US (1) | US7078423B2 (hu) |
EP (1) | EP1542980A1 (hu) |
JP (1) | JP2005535678A (hu) |
KR (1) | KR20050028038A (hu) |
CN (1) | CN1694875A (hu) |
AU (1) | AU2003249313A1 (hu) |
BR (1) | BR0312768A (hu) |
CA (1) | CA2492847A1 (hu) |
HU (1) | HUP0500871A3 (hu) |
IL (1) | IL166331A0 (hu) |
MX (1) | MXPA05000765A (hu) |
NZ (1) | NZ538313A (hu) |
PL (1) | PL374833A1 (hu) |
RU (1) | RU2005104429A (hu) |
WO (1) | WO2004009563A1 (hu) |
ZA (1) | ZA200501431B (hu) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087631B2 (en) * | 2002-07-18 | 2006-08-08 | Inotek Pharmaceuticals Corporation | Aryltetrazole compounds, and compositions thereof |
PA8578101A1 (es) * | 2002-08-13 | 2004-05-07 | Warner Lambert Co | Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz |
US7037927B2 (en) | 2003-10-16 | 2006-05-02 | Abbott Laboratories | Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
JP2008545627A (ja) | 2005-05-09 | 2008-12-18 | タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド | 腎結石症を治療する方法 |
CA2654915C (en) * | 2006-06-29 | 2015-07-28 | F.Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
CN101677999A (zh) * | 2006-11-13 | 2010-03-24 | 塔普医药产品公司 | 使用黄嘌呤氧化还原酶抑制剂保护肾功能的方法 |
US20090042887A1 (en) * | 2007-01-19 | 2009-02-12 | Tap Pharmaceutical Products, Inc. | Methods for Preventing or Reducing the Number of Gout Flares Using Xanthine Oxidoreductase Inhibitors and Anti-Inflammatory Agents |
WO2008126899A1 (ja) * | 2007-04-11 | 2008-10-23 | Kissei Pharmaceutical Co., Ltd. | 5員環へテロ環誘導体及びその医薬用途 |
MX2010003156A (es) * | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de aril amida substituida con tetrazol y usos de los mismos. |
US8410154B2 (en) * | 2008-04-30 | 2013-04-02 | Wellstat Therapeutics Corporation | Tetrazole compounds for reducing uric acid |
WO2011035332A1 (en) * | 2009-09-21 | 2011-03-24 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators |
JP5806221B2 (ja) * | 2009-10-13 | 2015-11-10 | ウェルスタット セラピューティクス コーポレイション | 尿酸を減少させる3−置換化合物 |
US9918964B2 (en) * | 2010-04-23 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration |
WO2012033941A1 (en) | 2010-09-10 | 2012-03-15 | Takeda Pharmaceuticals North America, Inc. | Methods for concomitant treatment of theophylline and febuxostat |
WO2014079850A1 (en) * | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Substituted heterocyclic derivatives |
WO2016187521A1 (en) * | 2015-05-21 | 2016-11-24 | South Connecticut State University | 5-substituted 1 h-tetrazole compounds, methods of synthesizing and therapeutic use |
WO2019132782A1 (en) * | 2017-12-29 | 2019-07-04 | Agency For Science, Technology And Research | Compounds for treating eye diseases and methods thereof |
CN114450285B (zh) * | 2019-06-25 | 2024-04-09 | 西诺普塞疗法公司 | 用于治疗眼部病症的化合物 |
CN112047896B (zh) * | 2020-10-12 | 2022-06-17 | 上海麦克林生化科技有限公司 | 芳环基或芳杂环基四氮唑的合成方法 |
CN114805233A (zh) * | 2022-03-30 | 2022-07-29 | 华南理工大学 | 苯基四氮唑类xor抑制剂及其制备方法与应用 |
CN115717258A (zh) * | 2022-12-09 | 2023-02-28 | 上海天承化学有限公司 | 一种用于印制线路板脉冲填孔电镀的整平剂及其应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049572A (en) * | 1987-04-06 | 1991-09-17 | Riker Laboratories, Inc. | Substituted di-t-butylphenols and anti-allergic use thereof |
IT1232252B (it) | 1989-02-22 | 1992-01-28 | Rotta Research Lab | Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione |
US5284954A (en) | 1990-09-10 | 1994-02-08 | Abbott Laboratories | Process for the preparation of tetrazoles |
IT1256870B (it) | 1992-02-13 | 1995-12-27 | Rotta Research Lab | Derivati bis-tetrazolici ad attivita' antiallergica e citoprotettiva |
US5364869A (en) | 1992-03-09 | 1994-11-15 | Abbott Laboratories | Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists |
DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO1995031445A1 (fr) | 1994-05-16 | 1995-11-23 | Sumitomo Chemical Company, Limited | Procede pour produire un compose de tetrazole et intermediaire prevu a cet effet |
US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
JPH1025294A (ja) | 1996-03-26 | 1998-01-27 | Akira Matsuda | 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤 |
JP4073489B2 (ja) | 1996-05-24 | 2008-04-09 | ニューロサーチ・アクティーゼルスカブ | 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法 |
US6696475B2 (en) | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
TR199902593T2 (xx) | 1997-04-22 | 2000-03-21 | Neurosearch A/S | �kame edilmi� fenil t�revleri, bunlar�n haz�rlanmas� ve kullan�m�. |
EP0990369B1 (en) | 1997-06-19 | 2003-07-09 | BRITISH TELECOMMUNICATIONS public limited company | Sound reproduction system |
ES2199336T3 (es) | 1997-08-08 | 2004-02-16 | Rotta Research Laboratorium S.P.A. | Una composicion farmaceutica novedosa para inhalacion que contiene cr 2039 (andolast). |
WO1999024038A1 (en) | 1997-11-07 | 1999-05-20 | Johns Hopkins University | Methods for treatment of disorders of cardiac contractility |
AU1457299A (en) | 1997-11-12 | 1999-05-31 | Ariad Pharmaceuticals, Inc. | Novel signal transduction inhibitors, compositions containing them |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
BR9914638A (pt) | 1998-10-22 | 2001-07-03 | Neurosearch As | Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo |
EP1283036B2 (de) | 1998-11-13 | 2020-01-01 | Jagotec AG | Multidosis-Trockenpulverinhalator mit Pulverreservoir |
JP4598278B2 (ja) | 1999-04-28 | 2010-12-15 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppar受容体リガンドとしてのジアリール酸誘導体 |
US6281222B1 (en) | 1999-08-19 | 2001-08-28 | Inotek Corporation | Compositions and method for treatment of acetaminophen intoxication |
EP1267874A2 (en) | 2000-03-09 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Therapeutic uses of ppar mediators |
DE10023430A1 (de) | 2000-05-12 | 2001-11-15 | Bayer Ag | Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe |
EP1296977A1 (en) | 2000-06-23 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
CN1558762A (zh) | 2001-09-14 | 2004-12-29 | ŵ��Ų�ڿ˹�˾ | R-态胰岛素六聚物的HisB10Zn2+位点的新配体 |
-
2002
- 2002-07-18 US US10/197,609 patent/US7078423B2/en not_active Expired - Fee Related
-
2003
- 2003-07-17 NZ NZ538313A patent/NZ538313A/en unknown
- 2003-07-17 HU HU0500871A patent/HUP0500871A3/hu unknown
- 2003-07-17 AU AU2003249313A patent/AU2003249313A1/en not_active Abandoned
- 2003-07-17 RU RU2005104429/04A patent/RU2005104429A/ru not_active Application Discontinuation
- 2003-07-17 KR KR1020057000943A patent/KR20050028038A/ko not_active Application Discontinuation
- 2003-07-17 EP EP03765715A patent/EP1542980A1/en not_active Withdrawn
- 2003-07-17 CA CA002492847A patent/CA2492847A1/en not_active Abandoned
- 2003-07-17 JP JP2004523556A patent/JP2005535678A/ja active Pending
- 2003-07-17 CN CNA038222353A patent/CN1694875A/zh active Pending
- 2003-07-17 WO PCT/US2003/022462 patent/WO2004009563A1/en not_active Application Discontinuation
- 2003-07-17 BR BR0312768-0A patent/BR0312768A/pt not_active Application Discontinuation
- 2003-07-17 MX MXPA05000765A patent/MXPA05000765A/es unknown
- 2003-07-17 PL PL03374833A patent/PL374833A1/xx unknown
-
2005
- 2005-01-17 IL IL16633105A patent/IL166331A0/xx unknown
- 2005-02-17 ZA ZA200501431A patent/ZA200501431B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003249313A1 (en) | 2004-02-09 |
WO2004009563A1 (en) | 2004-01-29 |
HUP0500871A3 (en) | 2006-11-28 |
EP1542980A1 (en) | 2005-06-22 |
NZ538313A (en) | 2005-09-30 |
US20040019208A1 (en) | 2004-01-29 |
ZA200501431B (en) | 2006-02-22 |
PL374833A1 (en) | 2005-10-31 |
CA2492847A1 (en) | 2004-01-29 |
BR0312768A (pt) | 2005-05-10 |
KR20050028038A (ko) | 2005-03-21 |
CN1694875A (zh) | 2005-11-09 |
MXPA05000765A (es) | 2005-10-19 |
IL166331A0 (en) | 2006-01-16 |
JP2005535678A (ja) | 2005-11-24 |
RU2005104429A (ru) | 2005-08-27 |
US7078423B2 (en) | 2006-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0500871A2 (hu) | 5-Ariltetrazol-vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
CY1108583T1 (el) | Μεθοδος για θεραπεια σοβαρης καρδιακης ανεπαρκειας και φαρμακο για αυτη | |
RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
ATE369353T1 (de) | Medizinisch verwendbare arylethanolamin verbindungen | |
RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
BRPI0509467A (pt) | compostos macrocìclicos como inibidores de replicação viral | |
AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
RU2012146986A (ru) | Цефемовые соединения, содержащие катехольную группу | |
TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
RU2007141398A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИЗОИНДОЛОВ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ АКТИВНОСТИ БЕЛКА-ШАПЕРОНА Hsp90 | |
HUP0401638A2 (hu) | Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények | |
AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
NO20065469L (no) | Behandling av infeksjonssykdommer. | |
DE602006017728D1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
RU2008113187A (ru) | Лечение аутоиммунных заболеваний | |
HUP0300578A2 (hu) | Alkilezett imidazopiridinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
BRPI0508079A (pt) | composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c | |
RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
MX2024001777A (es) | Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. | |
RU2005133093A (ru) | Соединения для лечения флавивирусных инфекций | |
RU2004122427A (ru) | Пирролидин-2-оны в качестве ингибиторов фактора ха | |
ATE536178T1 (de) | Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |